Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Office of Women’s Health director named

Executive Summary

FDA names Kathleen Uhl as director of the Office of Women's Health, effective Dec. 15. Uhl has been with the Center for Drug Evaluation & Research since 1998, most recently serving as the team leader for the Pregnancy & Lactation Labeling Team in the Office of New Drugs. Uhl will replace Theresa Toigo, who took over as acting director of the women's health office after Susan Wood resigned in protest of FDA's handling of an OTC switch application for Barr's emergency contraceptive Plan B (1"The Pink Sheet" Sept. 6, 2005, p. 6)...

You may also be interested in...

Plan B Delay Draws Criticism From Congress, Academia, FDA Official

FDA's handling of Barr's application to switch Plan B over the counter could elicit heightened external scrutiny of the agency's ability to make drug approval decisions based solely on science and public health

UK: Commercial Framework Sheds Light On Working With NHS And NICE

The final text brings some changes, including the introduction of an escalation process when companies and NHS England cannot agree.

Coherus Aiming For More Than 10% Slice Of US Adalimumab Market

Coherus BioSciences is aiming to translate the success of its comprehensive biosimilar pegfilgrastim strategy to adalimumab, with plans to capture at least 10% of the US market upon formation in 2023. Management summarized the firm’s expectations during the company’s fourth-quarter earnings call, which revealed a downturn in pegfilgrastim sales and profitability.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts